Parasite glycoconjugates. Part 5.<sup>1</sup> Blockwise approach to oligo(glycosyl phosphates): chemical synthesis of a terminal tris(glycobiosyl phosphate) fragment of *Leishmania donovani* antigenic lipophosphoglycan

### Andrei V. Nikolaev,<sup>\*,a</sup> Trevor J. Rutherford,<sup>b</sup> Michael A. J. Ferguson<sup>b</sup> and John S. Brimacombe<sup>a</sup>

<sup>a</sup> Department of Chemistry, University of Dundee, Dundee DD1 4HN, UK

<sup>b</sup> Department of Biochemistry, University of Dundee, Dundee DD1 4HN, UK

The model tetramannosyl triphosphate 7 and the hexaglycosyl triphosphate 8, which is a terminal fragment of the phosphoglycan portion of *Leishmania donovani* lipophosphoglycan, have been synthesized. Elongation of the chain was performed using the glycosyl hydrogenphosphonate method to couple together two phosphodiester blocks.

#### Introduction

In Part 4<sup>1</sup> of this series, we disclosed our interest in the synthesis of phosphorylated oligosaccharide fragments of the structure of the antigenic lipophosphoglycan (LPG) of *Leishmania donovani*, a protozoan parasite that causes visceral leishmaniasis. This, often fatal, disease is one of a variety of diseases in the tropics and subtropics caused by the *Leishmania*. We resume our exploration of the chemical synthesis of oligo(glycosyl phosphate) fragments of *L. donovani* LPG by reporting a different approach to those used previously (see below). The natural occurrence of phosphoglycans composed of glycosyl phosphate (or oligosyl phosphate) repeat units as surface antigens of some protozoa<sup>2</sup> and yeasts,<sup>3</sup> as well as being the immunologically active components of the cell wall or capsule of numerous bacteria,<sup>4</sup> upholds the need for the development of potential routes to these biopolymers.

Since the glycosyl hydrogenphosphonate method <sup>5–7</sup> provides an efficient means of constructing a phosphodiester linkage between the anomeric (i.e., hemiacetal) and other hydroxy groups, three major strategic approaches to oligo- and poly-(glycosyl phosphates) can be contemplated. They are: (1) the polycondensation of a partially protected glycosyl (or oligosyl) H-phosphonate derivative; (2) the stepwise chain elongation using protected glycosyl (or oligosyl) H-phosphonates for the successive introduction of the sugar phosphate residues; and (3) the block synthesis, involving the H-phosphonate condensation of two phosphodiester units (or blocks). Application of the polycondensation<sup>8</sup> and stepwise<sup>1,9</sup> approaches to phosphoglycan synthesis has been described recently. We now report how the blockwise approach, involving the coupling of a glycosyl H-phosphonate phosphodiester block and a monohydroxylic phosphodiester block, followed by oxidation of the newly formed H-phosphonic diester to the phosphate (Scheme 1), can be equally effective in phosphoglycan synthesis.

#### **Results and discussion**

The model protected tetramannosyl triphosphate 7 (Scheme 2), containing alternate  $(1\rightarrow 4)$ - and  $(1\rightarrow 6)$ -phosphodiester linkages, was synthesized using 2,3,4-tri-*O*-benzoyl-6-*O*-dimethoxytrityl- $\alpha$ -D-mannosyl H-phosphonate 1<sup>9</sup> and 1,2,3,6-tetra-*O*-benzoyl- $\alpha$ -D-mannopyranose 2<sup>1</sup> as the starting materials. Condensation of these compounds in pyridine in the presence of pivaloyl chloride, followed by *in situ* oxidation of the resulting H-phosphonic diester with iodine in aq. pyridine,



Scheme 1

gave the key  $(1\rightarrow 4)$ -linked dimannosyl phosphoric diester 3, which could be used to prepare both the monohydroxylic and H-phosphonate blocks 5 and 6, respectively.

Brief treatment of the synthon 3 with 1% CF<sub>3</sub>CO<sub>2</sub>H (TFA) in CH<sub>2</sub>Cl<sub>2</sub> removed the dimethoxytrityl (DMT) group and gave the 6'-monohydroxylic phosphodiester derivative 5 in 86% overall yield (based on the tetrabenzoate 2). Selective 1-O-debenzoylation of the phosphate 3 with dimethylamine <sup>1,5-7,9</sup> furnished the  $\alpha$ -hydroxy compound 4 (78%, based on the tetrabenzoate 2), which on phosphitylation with triimidazolyl-phosphine (prepared from PCl<sub>3</sub>, imidazole and Et<sub>3</sub>N) and subsequent mild hydrolysis gave the mannosyl H-phosphonate 4-(mannosyl phosphate) block 6 in 75% yield. It is notable that phosphitylation of the hemiacetal 4 ( $\longrightarrow$  6) required a much longer time (27 h) than that (35 min) of unphosphorylated mono- and di-saccharide derivatives.<sup>1,6-9</sup> When the reaction



Scheme 2 Reagents: i, (a) Me<sub>3</sub>CCOCl, pyridine; (b) I<sub>2</sub>, pyridinewater; ii, Me<sub>2</sub>NH, MeCN–THF-toluene; iii, TFA, CH<sub>2</sub>Cl<sub>2</sub>; iv, (a) triimidazolylphosphine, MeCN–pyridine; (b) Et<sub>3</sub>NHHCO<sub>3</sub>, water (pH 7)

with phosphodiester 4 was stopped after 1.5 h, the H-phosphonate 6 and the starting material were isolated in 43 and 33% yield, respectively.

The structure of compound **6** was supported by electrospray [ES(-)] mass spectrometry  $(m/z \ 705.3, [\text{M} - 2 \ \text{Et}_3\text{N} - 2 \ \text{H}]^{2^-})$  and NMR data. The presence of the H-phosphonic monoester moiety and the  $(1\rightarrow 4)$ -phosphodiester linkage was evident from the <sup>31</sup>P and <sup>1</sup>H NMR spectra:  $\delta_P \ 0.88 \ (\text{dd}, \ ^1J_{P,H} \ 637.7, \ ^3J_{P,H} \ 8.7 \ \text{Hz}, P), -3.37 \ (\text{dd}, \ ^3J_{P,H} \ 7.0 \ \text{and} \ 10.5 \ \text{Hz}, P'); \ \delta_H \ 5.32 \ (q, \ J_{3,4} = \ J_{4,5} = \ J_{4,P'} = 10.5 \ \text{Hz}, 4-\text{H}), \ 5.80 \ (\text{dd}, \ J_{1,2} \ 2.0, \ J_{1,P} \ 8.7 \ \text{Hz}, 1-\text{H}), \ 5.87 \ (\text{br d}, \ J_{1',P'} \ 7.0 \ \text{Hz}, 1'-\text{H}), \ 7.14 \ (\text{d}, \ ^1J_{H,P} \ 637.7 \ \text{Hz}, \text{HP}).$  The  $\alpha$ -configuration of each of the D-mannosyl residues followed from the characteristic positions of the 1-, 3- and 5-H resonances of Man and Man' (see Experimental section). The structure of compound **4** was established in a similar manner, while that of compound **5** was confirmed by  $^{13}$ C and  $^{31}$ P NMR and ES(-) mass spectrometric data (see Experimental section).

Coupling of the H-phosphonate block **6** with the hydroxylic acceptor **5** and *in situ* oxidation, as described in the preparation of phosphodiester **3**, gave the protected tetramannosyl triphosphate **7** in 67% yield. The structure of this compound was confirmed by ES-MS(-) (m/z 852.9, [M - 3 Et<sub>3</sub>N - 3 H]<sup>3-</sup>) and NMR data. The <sup>31</sup>P NMR spectrum contained two characteristic signals, in the ratio 1:2, at  $\delta_{\rm P} - 2.36$  (q, <sup>3</sup> $J_{\rm P,H}$  6.8

Hz, P') and -3.20 (dd,  ${}^{3}J_{P,H}$  7.7 and 10.0 Hz, P + P"). The presence of one (1 $\rightarrow$ 6)- and two (1 $\rightarrow$ 4)-phosphodiester linkages followed from the position and spin-coupling of the C-1' and C-4; C-1" and C-6'; and C-1"" and C-4" signals in the  ${}^{13}$ C NMR spectrum (see Experimental section). These signals were shifted as a result of the  $\alpha$ -effect of phosphorylation and were coupled with phosphorus as well as were the signals of the neighbouring carbon atoms (C-3 and -5; C-2' and -5'; C-2", -3" and -5"; and C-2""). Analogous couplings of the coincident 4- and 4"-H signals [ $\delta_{\rm H}$  5.35 (2 H, q,  $J_{3,4} = J_{4,5} = J_{4,P} = 10.0$  Hz)] in the  ${}^{1}$ H NMR spectrum clearly indicated that both Man and Man" are phosphorylated at position-4.

As already demonstrated with the dimannosyl phosphate 3, it should also be possible to convert the tetramannosyl triphosphate 7 into both monohydroxylic and H-phosphonate tetrasaccharide blocks for subsequent coupling to form a linear octamannosyl heptaphosphate. A block synthesis would be particularly advantageous in the preparation of the regular phosphoglycans, since fewer coupling steps are required than in stepwise elongation of the chain.

$$\alpha$$
-D-Manp-(1 $\rightarrow$ 2)- $\alpha$ -D-Manp-(1-PO<sub>3</sub>H-[-6)- $\beta$ -D-Galp-(1 $\rightarrow$   
4)- $\alpha$ -D-Manp-(1-PO<sub>3</sub>H-]<sub>2</sub>-O[CH<sub>2</sub>]<sub>8</sub>CH=CH<sub>2</sub>  
**8**

$$\beta$$
-D-Gal $p$ -(1 $\rightarrow$ 4)- $\alpha$ -D-Man $p$ -1-PO<sub>3</sub>H-O[CH<sub>2</sub>]<sub>8</sub>CH=CH<sub>2</sub>  
9

The tris(glycobiosyl phosphate) 8, representing a fragment of the structure at the non-reducing end of the phosphoglycan portion of *Leishmania donovani* LPG, was prepared using the blockwise approach as well. It consists of two galactosylmannosyl phosphate repeat units capped by a D-mannobiosyl phosphate unit. In this context, a shorter fragment 9, representing just one glycobiosyl phosphate repeat unit of the phosphoglycan, was synthesized. Both compounds contain a dec-9-enyl moiety and are designed to be used for both biosynthetic studies and the preparation of artificial antigens. The chemical synthesis of four related fragments of *Leishmania donovani* phosphoglycan has been described recently.<sup>1</sup>

The synthesis of the hexaglycosyl triphosphate **8** was accomplished from recently described <sup>1</sup> disaccharide derivatives **10** and **11**, which served for the preparation of both the tetrasaccharide H-phosphonate block **15** (Scheme 3) and the disaccharide monohydroxylic block **17** (Scheme 4).

Standard acetylation of the hemiacetal 11 (Scheme 3), followed by cleavage of the dimethoxytrityl group from the product under acidic conditions, resulted in the 6'-monohydroxylic compound 12 (73%). Condensation of the mannobiosyl H-phosphonate 10 with the disaccharide 12 in the presence of adamantane-1-carbonyl chloride, followed by *in situ* oxidation with iodine in aq. pyridine ( $\longrightarrow$  13) and subsequent selective anomeric deacetylation with dimethylamine, gave the tetrasaccharide  $\alpha$ -hemiacetal derivative 14 in 78% overall yield. This compound was converted into the glycobiosyl H-phosphonate 6'-(mannobiosyl phosphate) block 15 (65%) by phosphonylation using the procedure already described.

The structure of compound 15 was confirmed by fast-atom bombardment [FAB(+)] mass spectrometry (m/z 2080.47, [M – Et<sub>3</sub>N + H]<sup>+</sup>) and <sup>31</sup>P and <sup>1</sup>H NMR data [ $\delta_P$  1.68 (dd, <sup>1</sup> $J_{P,H}$  640.0, <sup>3</sup> $J_{P,H}$  8.7 Hz, P), -2.54 (dt, <sup>3</sup> $J_{P,H}$  8.5 and 10.5 Hz, P');  $\delta_H$  5.67 (dd,  $J_{1,2}$  1.5,  $J_{1,P'}$  8.5 Hz, 1-H Man'), 5.72 (br d,  $J_{1,P}$  8.7 Hz, 1-H, Man), 7.01 (d, <sup>1</sup> $J_{H,P}$  640.0 Hz, HP)]. The  $\alpha$ -configuration of the H-phosphonylated and phosphorylated D-mannose residues was evident from the characteristic values (176.1 and 170.2 Hz, respectively) of <sup>1</sup> $J_{C,H}$  for the C-1 signals of Man and Man' in the <sup>13</sup>C NMR spectrum (sce Experimental section).

To prepare the monohydroxylic block 17 (Scheme 4), the hemiacetal 11 was first H-phosphonylated to give the



Scheme 3 Reagents: i, (a)  $Ac_2O$ , pyridine; (b) TFA,  $CH_2Cl_2$ ; ii, (a) adamantane-1-carbonyl chloride, pyridine; (b)  $I_2$ , pyridine-water; iii,  $Me_2NH$ , MeCN-THF; iv, (a) triimidazolylphosphine, MeCN; (b)  $Et_3NHHCO_3$ , water (pH 7)

glycobiosyl H-phosphonate **16** (92%), as described in ref. 1. Condensation of the derivative **16** with dec-9-en-1-ol, followed by oxidation, as described for the preparation of the phosphodiester **13**, and subsequent dedimethoxytritylation with 1% TFA in  $CH_2Cl_2$  gave the disaccharide phosphate derivative **17** in 90% overall yield.

Coupling of the H-phosphonate phosphodiester block 15 and the monohydroxylic phosphodiester block 17 was accomplished in the prescribed manner (with adamantane-1-carbonyl chloride), after which *in situ* oxidation with iodine afforded the protected hexasaccharide triphosphate 18 in 62% yield. The deprotected tris(glycobiosyl phosphate) 8 and dec-9-enyl glycobiosyl phosphate 9 were readily obtained from the derivatives 18 and 17, respectively, by *O*-deacylation with 0.05 mol  $dm^{-3}$  methanolic sodium methoxide.

The structures of the compounds **8**, **9**, **17** and **18** were confirmed by NMR and mass spectrometric data (see Experimental section). For the monophosphates **17** and **9** the <sup>31</sup>P NMR spectra exhibited just single signals at  $\delta_P - 1.40$  and -1.04, respectively. The <sup>31</sup>P NMR spectra of the triphosphates **18** and **8** consisted of three and two signals, respectively:  $\delta_P - 1.40$  (P), -2.56 (P") and -3.05 (P') for the protected derivative **18**, and -0.91 (P) and -1.24 (P' + P") in the ratio 1:2 for the deprotected oligomer **8**.

The presence of the  $(1\rightarrow 6)$ -phosphodiester linkages in compound 8 was established from the C-1 and C-2 signals of the corresponding D-mannose units and the C-5 and C-6 signals of the corresponding D-galactose units in the <sup>13</sup>C NMR spectrum, while the presence of the  $(1 \rightarrow 1)$ -phosphodiester linkage at the reducing terminus of each of the compounds 8 and 9 was likewise confirmed by the C-1 and C-2 signals of the D-mannose and the dec-9-enyl units (see Table 1). These signals were shifted as a result of the  $\alpha$ - and  $\beta$ -effects of phosphorylation and were coupled with phosphorus. The a-configuration of the Dmannosyl phosphate fragments followed from the positions of the C-3 and C-5 resonances of Man, Man' and Man". The chemical shifts of these signals are close to those of C-3 and C-5 of  $\alpha$ -D-mannopyranosyl phosphate,<sup>10</sup> taking into account the influence of the glycosyl substituents at position-4 (of Man and Man') and position-2 (of Man").

The molecular masses of the oligomers **8**, **9**, **17** and **18**, were confirmed by ES(-) and FAB(+) mass spectrometry. The dominant signals in the spectra corresponded to the pseudo-molecular ions for the monophosphates **9** (m/z 559.3,  $[M - Et_3N - H]^-$ ) and **17** (m/z 1287.0,  $[M + H]^+$ ) and for the triphosphates **8** (m/z 455.3,  $[M - 3 Et_3N - 3 H]^{3-}$ ) and **18** (m/z 1052.3,  $[M - 3 Et_3N - 3 H]^{3-}$ ).

The reasonably high yields of the oligomers 7 (67%) and 18 (62%) achieved in coupling of the H-phosphonate and the monohydroxylic phosphodiester blocks [(6 + 5) and (15 + 17), respectively] indicate that side-reactions, possibly involving the reaction of the activated H-phosphonate with intersaccharide phosphate groups, did not intervene to a significant extent.

It has been demonstrated earlier <sup>11</sup> that the mixed anhydride **19** is the main reactive intermediate in the glycosyl phosphosugar synthesis from glycosyl H-phosphonates in the presence of pivaloyl chloride. The analogous H-phosphono-(adamantane-1-carbonic) anhydride **20** fulfils the same role when the H-phosphonate condensation is accomplished in the presence of adamantane-1-carbonyl chloride. We presume that the activated anhydrides **19** and **20** can react, in principle, with both the intersaccharide phosphate and the alcoholic hydroxy group. The first reaction results in an unstable glycosyl H-phosphono(phosphoric) anhydride and seems to be reversible,<sup>†</sup> whereas the second reaction results in the irreversible formation of the hydrogenphosphonic diester (see Scheme 1), which has to be oxidized further to the target oligo(glycosyl phosphate).

In accord with data<sup>13</sup> describing the mechanism of the Hphosphonate condensation in pyridine, the solvent can participate in the reaction as a nucleophilic catalyst to assist the formation of the H-phosphonic diester *via* the activated pyridinium intermediate **21**.

To summarize, a new blockwise approach has been introduced into the synthetic chemistry of the phosphoglycans composed of glycosyl phosphate residues. A biological

<sup>&</sup>lt;sup>†</sup> This could be supported by data <sup>12</sup> describing the presence of equilibrium in the system: ethyl H-phosphono(pivalic) anhydride  $\rightleftharpoons$  diethyl H-pyrophosphonate, which is to the left.



Scheme 4 Reagents: i, (a) triimidazolylphosphine, MeCN; (b) Et<sub>3</sub>NHHCO<sub>3</sub>, water (pH 7); ii, (a) adamantane-1-carbonyl chloride, pyridine; (b) I<sub>2</sub>, pyridine-water; iii, TFA, CH<sub>2</sub>Cl<sub>2</sub>; iv, NaOMe, MeOH



evaluation of compounds 8 and 9 and related synthetic fragments of *L. donovani* LPG will be published elsewhere<sup>14</sup> in due course.

#### Experimental

#### **General procedures**

Optical rotations were measured with a Perkin-Elmer 141 polarimeter;  $[\alpha]_D$ -values are given in units of  $10^{-1}$  deg cm<sup>2</sup> g<sup>-1</sup>. NMR spectra (<sup>1</sup>H at 200 and 500 MHz, <sup>13</sup>C-{<sup>1</sup>H} at 50.3 and 125 MHz, and <sup>31</sup>P at 81 and 202.5 MHz) were recorded with Bruker AM-200 and AM-500 spectrometers for solutions in CDCl<sub>3</sub>, unless otherwise indicated. Chemical shifts ( $\delta$  in ppm) are given relative to those for Me<sub>4</sub>Si (for <sup>1</sup>H and <sup>13</sup>C) and external aq. 85% H<sub>3</sub>PO<sub>4</sub> (for <sup>31</sup>P); *J*-values are given in Hz. FAB mass spectra were recorded with a VG 70-250 SE mass spectrometer using an Ion-tech xenon gun. ES mass spectra were recorded with a VG Biotech, UK). TLC was performed on Polygram Sil G/UV<sub>254</sub> (Macherey-Nagel, Germany) with *A*, chloroform–methanol (95:5); *B*,

chloroform-methanol (92:8); C, chloroform-methanol (9:1); D, chloroform-methanol-water (10:10:3); and E, tolueneethyl acetate (8:2) as developers and detection by charring with sulfuric acid-water-ethanol (15:85:5). Column chromatography was performed on Kieselgel 60 (0.040–0.063 mm) (Merck). Pivaloyl chloride and adamantane-1-carbonyl chloride were purchased from Aldrich. Pyridine, acetonitrile and tetrahydrofuran (THF) were freshly distilled from CaH<sub>2</sub>. Solutions worked up were concentrated under reduced pressure at <40 °C.

## 2,3,6-Tri-*O*-benzoyl- $\alpha$ -D-mannopyranose 4-[2,3,4-tri-*O*-benzoyl-6-*O*-(*p*,*p*'-dimethoxytrityl)- $\alpha$ -D-mannopyranosyl phosphate], triethylammonium salt 4

A mixture of compounds 1<sup>9</sup> (471 mg, 0.49 mmol) and 2<sup>1</sup> (250 mg, 0.42 mmol) was dried by evaporation of pyridine (3 × 3 cm<sup>3</sup>) therefrom. The residue was dissolved in pyridine (3 cm<sup>3</sup>), pivaloyl chloride (0.151 cm<sup>3</sup>, 1.23 mmol) was added, and the mixture was stirred at 20 °C for 10 min, whereafter a freshly prepared solution of iodine (254 mg, 1 mmol) in pyridine–water (95:5; 4 cm<sup>3</sup>) was added. After 10 min, CHCl<sub>3</sub> was added, and the solution was washed successively with ice-cold 1 mol dm<sup>-3</sup> aq. Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> and cold 0.5 mol dm<sup>-3</sup> aq. triethylammonium (TEA) hydrogen carbonate (pH 7.0–7.5), dried by filtration through cotton wool, and concentrated. TLC (solvent *A*) of the residue showed the formation of one major product ( $R_f$  0.54; presumed to be the phosphodiester 3). After drying *in vacuo*, the residue (800 mg; amorphous solid) then was divided into two

**Table 1** <sup>13</sup>C NMR data ( $D_2O$ ;  $\delta_C$  in ppm; J in Hz) for phosphooligosaccharides **9** and **8** ( $J_{C,P}$ -values in parentheses)

| Residue    | Atom   | 9 <sup>a</sup>  | <b>8</b> <sup><i>a</i></sup>  |
|------------|--|---|---|
| Dec-9-enyl | OCH <sub>2</sub><br>OCH <sub>2</sub> CH <sub>2</sub><br>CCH <sub>2</sub> C | 67.81d (5.5)<br>30.95d (5.5)<br>25.96, 29.22, 29.32,<br>29.41, 29.57, 34,19 | 67.84br<br>31.02d (5.5)<br>26.03, 29.27, 29.37<br>29.48, 29.62, 34,19 |
|            | -CH=   | 141.64  | 141.67  |
|            | =CH <sub>2</sub>   | 115.04  | 115.13  |
| Man        | C-1  | 96.84d (5.6)  | 96.90d (5.6)  |
|            | C-2  | 71.29d (7.4)  | 71.18d (7.4)  |
|            | C-3  | 69.73   | 70.00   |
|            | C-4  | 76.99   | 78.22   |
|            | C-5  | 73.43   | 73.52   |
|            | C-6  | 61.20   | 61.44   |
| Gal        | C-1  | 104.15  | 104.51  |
|            | C-2  | 72.07   | 71.98   |
|            | C-3  | 73.64   | 73.52   |
|            | C-4  | 69.85   | 69.25   |
|            | C-5  | 76.48   | 74.56d (7.4)  |
|            | C-6  | 62.23   | 65.42d (5.6)  |
| Man'       | C-1  |   | 96.90d (5.6)  |
|            | C-2  |   | 71.18d (7.4)  |
|            | C-3  |   | 70.00   |
|            | C-4  |   | 78.12   |
|            | C-5  |   | 73.52   |
|            | C-6  |   | 61.44   |
| Gal'       | C-1  |   | 104.51  |
|            | C-2  |   | 71.98   |
|            | C-3  |   | 73.52   |
|            | C-4  |   | 69.25   |
|            | C-5  |   | 74.56d (7.4)  |
|            | C-6  |   | 65.42d (5.6)  |
| Man″       | C-1  |   | 95.85d (3.7)  |
|            | C-2  |   | 80.16d (8.1)  |
|            | C-3  |   | 70.67   |
|            | C-4  |   | 67.84   |
|            | C-5  |   | 75.05   |
|            | C-6  |   | 62.04   |
| Man‴       | C-1  |   | 103.38  |
|            | C-2  |   | 71.14   |
|            | C-3  |   | 71.48   |
|            | C-4  |   | 67.84   |
|            | C-5  |   | 74.41   |
|            | C-6  |   | 62.04   |

<sup>*a*</sup> Additional signals for Et<sub>3</sub>NH<sup>+</sup> ( $\delta_c$  9.34–9.43 and  $\delta_c$  47.81–47.85) were present.

portions, one of which (300 mg) was used to prepare the detritylated compound 5 (see below). To the other portion (500 mg) dissolved in MeCN–THF–toluene (4:1:1; 6 cm<sup>3</sup>) was added anhydrous dimethylamine (0.112 cm<sup>3</sup>, 1.68 mmol) at -20 °C, and the mixture was then kept at 20 °C for 16 h (with monitoring by TLC in solvent A), whereafter a second portion of dimethylamine (0.12 cm<sup>3</sup>, 1.80 mmol) was added. After a further 22 h, the mixture was concentrated and MeCN was evaporated off from the residue. Column chromatography  $[CH_2Cl_2-MeOH-Et_3N, (98.8:0.2:1) \longrightarrow (95:4:1)]$  gave the disaccharide monophosphate derivative 4 (295 mg, 78%) as an amorphous solid;  $[\alpha]_D^{22} - 60$  (c 1, CHCl<sub>3</sub>);  $R_f 0.31$  (solvent A), 0.63 (solvent C);  $\delta_H 1.39$  (9 H, t, 3 × MeCH<sub>2</sub>), 2.82 (6 H, q,  $3 \times \text{MeC}H_2$ ), 2.95 (1 H, dd,  $J_{6a',6b'}$  10.5, 6'-H<sup>a</sup>), 3.21 (1 H, dd,  $J_{5',6b'}$  1.4, 6'-H<sup>b</sup>), 3.62 and 3.63 (6 H, 2 s, 2 × MeO), 4.29 (1 H, ddd, J<sub>5',6a'</sub> 2.4, 5'-H), 4.35 (1 H, ddd, J<sub>5,6a</sub> 4.0, 5-H), 4.78 (1 H, dd, J<sub>6a,6b</sub> 12.5, 6-H<sup>a</sup>), 4.99 (1 H, dd, J<sub>5,6b</sub> 1.5, 6-H<sup>b</sup>), 5.31 (1 H, q,  $J_{3,4} = J_{4,5} = J_{4,P} = 10.0, 4$ -H), 5.38 (1 H, d,  $J_{1,2}$  1.5, 1-H), 5.64 (2 H, m,  $J_{2,3}$  3.3, 2- and 3-H), 5.82 (1 H, dd,  $J_{2',3'}$  3.5, 3'-H), 5.83 (1 H, dd, 2'-H), 5.86 (1 H, dd,  $J_{1',2'}$  2.0,  $J_{1',P}$  8.0, 1'-H), 6.27 (1 H, dd,  $J_{3',4'} = J_{4',5'} = 10.5, 4'$ -H), 6.60 and 6.67 (4 H, 2 d, o-protons of 2  $\times$  C<sub>6</sub>H<sub>4</sub>) and 7.05–8.15 (39 H, m, m-protons of 2 × C<sub>6</sub>H<sub>4</sub>, 7 × Ph);  $\delta_{\rm C}$  8.75 and 45.55 (Et), 55.01 and 55.06 (MeO), 60.88 (C-6'), 63.18 (C-6), 66.22 (C-4'), 69.58 (d,  $J_{C,P}$  5.4, C-4), 70.33 (d,  $J_{C,P}$  5.4, C-5), 70.75 (C-3'), 70.88 (d,  $J_{C,P}$  5.2, C-2'), 70.90 (C-2), 71.18 (C-5'), 71.22 (br, C-3), 85.55 (Ar<sub>3</sub>C), 92.13 (C-1), 94.12 (d,  $J_{C,P}$  4.1, C-1'), 112.91, 112.99, 126.32– 133.17, 135.71, 136.07, 144.83, 158.04 and 158.10 (C<sub>6</sub>H<sub>4</sub> and Ph) and 166.03–166.62 (PhCO<sub>2</sub>);  $\delta_P$  – 2.50 (dd,  $J_{P,H}$  8.0 and 10.0); ES-MS(-): m/z 941.3 (18%, [M – Et<sub>3</sub>N – (MeOC<sub>6</sub>H<sub>4</sub>)<sub>2</sub>PhC – PhCO + H]<sup>-</sup>), 1045.2 (17, [M – Et<sub>3</sub>N – (MeOC<sub>6</sub>H<sub>4</sub>)<sub>2</sub>PhC]<sup>-</sup>), 1243.2 (7, [M – Et<sub>3</sub>N – PhCO]<sup>-</sup>) and 1347.3 (100, [M – Et<sub>3</sub>N – H]<sup>-</sup>) (C<sub>81</sub>H<sub>80</sub>-NO<sub>22</sub>P requires M, 1449.49).

#### 1,2,3,6-Tetra-O-benzoyl-α-D-mannopyranose 4-[2,3,4-tri-Obenzoyl-α-D-mannopyranosyl phosphate], triethylammonium salt 5

To a stirred and cooled (0 °C) solution of the crude phosphodiester **3** (300 mg, prepared in the preceding experiment) in CH<sub>2</sub>Cl<sub>2</sub> (15 cm<sup>3</sup>) was added TFA (0.15 cm<sup>3</sup>). After 1 min, the solution was washed successively with ice-cold saturated aq. NaHCO<sub>3</sub> and 0.5 mol dm<sup>-3</sup> aq. TEA hydrogen carbonate, dried by filtration through cotton wool, and concentrated. Column chromatography [CH<sub>2</sub>Cl<sub>2</sub>-MeOH-Et<sub>3</sub>N, (98.8:0.2:1)  $\longrightarrow$  (96:3:1)] of the residue gave the *monohydroxylic derivative* **5** (168 mg, 85.5% based on compound **2**) as an amorphous solid; [ $\alpha$ ]<sub>D<sup>2</sup></sub><sup>2</sup> - 33.5 (*c* 1, CHCl<sub>3</sub>);  $R_f$  0.40 (solvent *A*), 0.70 (solvent *C*);  $\delta_c$  9.61 and 45.70 (Et), 61.30 (C-6'), 63.40 (C-6), 66.91 (C-4'), 69.13 (d,  $J_{C,P}$  5.6, C-4), 69.51 (C-2), 69.95 (C-3'), 70.61 (d,  $J_{C,P}$  8.3, C-2'), 71.39 (d,  $J_{C,P}$  2.8, C-3), 72.07 (C-5'), 72.41 (d,  $J_{C,P}$  4.9, C-5), 91.32 (C-1), 94.10 (d,  $J_{C,P}$  4.9, C-1'), 128.10–129.70 and 132.90–133.20 (Ph) and 165.12–165.91 (PhCO<sub>2</sub>);  $\delta_P$  - 3.04 (dd,  $J_{P,H}$  7.0 and 10.0); ES-MS(-): m/z 1149.1 (100%, [M - Et<sub>3</sub>N - H]<sup>-</sup>) (C<sub>67</sub>H<sub>66</sub>-NO<sub>21</sub>P requires M, 1251.39).

#### 2,3,6-Tri-O-benzoyl- $\alpha$ -D-mannopyranosyl hydrogenphosphonate 4-[2,3,4-tri-O-benzoyl-6-O-(p, p'-dimethoxytrityl)- $\alpha$ -D-mannopyranosyl phosphate], bistriethylammonium salt 6

To a stirred solution of imidazole (432 mg, 6.32 mmol) in MeCN (4 cm<sup>3</sup>) at 0 °C were added phosphorus trichloride  $(0.166 \text{ cm}^3, 1.90 \text{ mmol})$  and then triethylamine  $(0.95 \text{ cm}^3, 6.65 \text{ cm}^3)$ mmol). The mixture was stirred for 15 min, after which a solution of compound 4 (270 mg, 0.186 mmol) in MeCNpyridine (2:1; 7 cm<sup>3</sup>) was added dropwise during 20 min at 0 °C. The mixture was stirred at 24 °C for 27 h and quenched with 1 mol dm<sup>-3</sup> aq. TEA hydrogen carbonate (3 cm<sup>3</sup>). The clear solution was stirred for 15 min, CHCl<sub>3</sub> (150 cm<sup>3</sup>) was added, and the organic layer was washed in turn with ice-water  $(2 \times 80 \text{ cm}^3)$  and cold 0.5 mol dm<sup>-3</sup> aq. TEA hydrogen carbonate  $(2 \times 80 \text{ cm}^3)$ , dried by filtration through cotton wool, and concentrated. Column chromatography [CH<sub>2</sub>Cl<sub>2</sub>-MeOH-Et<sub>3</sub>N,  $(98.8:0.2:1) \longrightarrow (95.1:3.9:1)$ ] gave the *H*-phosphonate phosphodiester derivative 6 (224 mg, 74.6%) as an amorphous solid;  $R_f$  0.29 (solvent C);  $\delta_H$  1.20 (18 H, t,  $6 \times MeCH_2$ ), 2.94 (12 H, q,  $6 \times MeCH_2$ ), 3.25 (2 H, m, 6'-H<sub>2</sub>), 3.62 and 3.63 (6 H, 2 s, 2  $\times$  MeO), 4.32 (1 H, br d, 5'-H), 4.57 (1 H, ddd, J<sub>5,6b</sub> 1.1, 5-H), 4.81 (1 H, dd, J<sub>5,6a</sub> 4.0, 6-H<sup>a</sup>), 5.05 (1 H, dd,  $J_{6a,6b}$  12.0, 6-H<sup>b</sup>), 5.32 (1 H, q,  $J_{3,4} = J_{4,5} = J_{4,P'} = 10.5, 4-H$ ), 5.69 (1 H, dd,  $J_{2,3}$  2.5, 3-H), 5.71 (1 H, dd, 2-H), 5.80 (1 H, dd,  $J_{1,2}$  2.0,  $J_{1,P}$  8.7, 1-H), 5.84 (1 H, dd,  $J_{2',3'}$  3.0, 3'-H), 5.86 (1 H, br, 2'-H), 5.87 (1 H, br d,  $J_{1',P'}$  7.0, 1'-H), 6.21 (1 H, dt 6.31 (1 H, t,  $J_{3',4'} = J_{4',5'} = 10.0, 4'$ -H), 6.61 and 6.67 (4 H, 2 d, o-protons of 2 ×  $C_6H_4$ ), 7.14 (1 H, d,  $J_{H,P}$  637.7, HP) and 7.00–8.11 (39 H, m, *m*-protons of 2  $\times$  C<sub>6</sub>H<sub>4</sub>, 7  $\times$  Ph);  $\delta_{\rm C}$  8.71 and 45.50 (Et), 54.89 and 54.91 (MeO), 60.75 (C-6'), 63.28 (C-6), 65.94 (C-4'), 69.61 (d,  $J_{C,P}$  4.7, C-4), 70.87 (C-3'), 70.98 (2 C, br, C-2 and -2'), 71.01 (d,  $J_{C,P} \sim 3.0$ , C-5), 71.20 (C-5'), 71.31 (d, J<sub>C,P</sub> 5.0, C-3), 85.43 (Ar<sub>3</sub>C), 92.92 (d, J<sub>C,P</sub> 3.4, C-1), 94.12 (d, J<sub>C,P</sub> 4.1, C-1'), 112.90, 112.95, 126.32–133.17, 135.70, 136.15, 144.80, 158.00 and 158.09 (C<sub>6</sub>H<sub>4</sub> and Ph) and 166.02–166.57 (PhCO<sub>2</sub>);  $\delta_{\rm P}$  0.88 (dd, <sup>1</sup>J<sub>P,H</sub> 637.7, <sup>3</sup>J<sub>P,H</sub> 8.7, P) and -3.37 (dd,  ${}^{3}J_{P,H}$  7.0 and 10.5, P'); ES-MS(-): m/z 705.3 (100%, [M - 2  $Et_3N - 2 H]^{2-}$  and 1411.3 (20,  $[M - 2 Et_3N - H]^{-}$ )  $(C_{87}H_{96}N_2O_{24}P_2 \text{ requires M, 1614.58}).$ 

# 1,2,3,6-Tetra-*O*-benzoyl- $\alpha$ -D-mannopyranose 4-[2,3,4-tri-*O*-benzoyl- $\alpha$ -D-mannopyranosyl phosphate 6-{2,3,6-tri-*O*-benzoyl- $\alpha$ -D-mannopyranosyl phosphate 4-[2,3,4-tri-*O*-benzoyl-6-*O*-(*p*,*p*'-dimethoxytrityl)- $\alpha$ -D-mannopyranosyl phosphate]}], tristriethylammonium salt 7

This compound was prepared by condensation of the Hphosphonate block 6 (130 mg, 0.08 mmol) and the monohydroxylic block 5 (75 mg, 0.06 mmol) in the presence of pivaloyl chloride (0.02 cm<sup>3</sup>, 0.185 mmol) in pyridine (0.5 cm<sup>3</sup>) during 30 min, followed by oxidation with iodine (40 mg, 0.157 mmol), as described in the synthesis of compound 4. Column chromatography [CH<sub>2</sub>Cl<sub>2</sub>-MeOH-Et<sub>3</sub>N, (98.5:0.5:1) (92:7:1)] gave the tetrasaccharide trisphosphate derivative 7 (115 mg, 67%) as an amorphous solid;  $[\alpha]_{D}^{24} - 57$  (c 1, CHCl<sub>3</sub>);  $R_{\rm f}$  0.43 (solvent C);  $\delta_{\rm H}$  1.15 (27 H, t, 9 × MeCH<sub>2</sub>), 2.75 (1 H, d,  $J_{6a''',6b'''}$  11.0,  $6'''-H^a$ ), 2.89 (18 H, q,  $9 \times MeCH_2$ ), 3.10 (1 H, d, 6"'-H<sup>b</sup>), 3.63 and 3.64 (6 H, 2 s,  $2 \times MeO$ ), 4.17 (3 H, m, 5'-H and 6'-H<sub>2</sub>), 4.44 (1 H, d, J<sub>4", 5"</sub> 10.0, 5""-H), 4.59 (2 H, m, 5- and 5"-H), 4.73 (1 H, br d, J<sub>6a,6b</sub> 12.0, 6-H<sup>a</sup>), 4.90 (1 H, d,  $J_{6a'',6b''}$  11.5, 6"-H<sup>a</sup>), 4.92 (1 H, dd,  $J_{5,6b}$  4.0, 6-H<sup>b</sup>), 5.12 (1 H, d, 6"-H<sup>b</sup>), 5.35 (2 H, q,  $J_{3,4} = J_{3'',4''} =$  $J_{4,5} = J_{4'',5''} = J_{4,P} = J_{4'',P''} = 10.0, 4- \text{ and } 4''-\text{H}), 5.59-5.89$ (11 H, m, 1'-, 1''-, 1'''-, 2-, 2'-, 2'''-, 3'-, 3''-, 3''- and 4'-\text{H}), 5.97 (1 H, dd, J<sub>2.3</sub> 3.0, 3-H), 6.25 (1 H, t, J<sub>3",4"</sub> 10.0, 4"'-H), 6.59 (5 H, m, 1-H and o-protons of  $2 \times C_6H_4$ ) and 7.00-8.22 (74 H, m, *m*-protons of  $2 \times C_6H_4$ ,  $14 \times Ph$ );  $\delta_c$  8.90 and 45.39 (Et), 54.94 and 54.96 (MeO), 60.68 (C-6"), 62.98 and 63.40 (C-6 and -6"), 64.95 (d, J<sub>C,P</sub> 4.2, C-6'), 65.97 (C-4""), 67.15 (C-4'), 68.97 and 69.23 (2 d,  $J_{C,P}$  5.2 and 5.5, C-4 and -4"), 69.60 (C-2), 70.28 (C-3'), 70.57 (d, J<sub>C,P</sub> 7.6, C-2'), 70.80 (C-3""), 70.85, 70.95 and 71.01 (3 d, J<sub>C,P</sub> 4.5, 4.5 and 4.9, C-2", -2''' and -5''), 71.10 (C-5'''), 71.25 (d,  $J_{C,P}$  7.6, C-5'), 71.34 (br, C-3"), 71.39 (d, J<sub>C,P</sub> 2.7, C-3), 72.94 (d, J<sub>C,P</sub> 4.2, C-5), 85.36 (Ar<sub>3</sub>C), 91.35 (C-1), 93.72 (d, J<sub>C,P</sub> 4.2, C-1"), 94.00 and 94.08 (2 d, J<sub>C.P.</sub> 4.5 and 4.4, C-1' and -1""), 112.80, 112.87, 126.28, 127.56-133.56, 135.55, 136.23, 144.86, 158.02 and 158.06 (C<sub>6</sub>H<sub>4</sub> and Ph) and 164.10–166.14 (PhCO<sub>2</sub>);  $\delta_{\rm P} = -2.36$  (q,  $J_{\rm P,H}$  6.8, P') and -3.20 (dd,  $J_{P,H}$  7.7 and 10.0, P + P'') (ratio 1:2); ES- $MS(-): m/z 852.9 (85\%, [M - 3 Et_3N - 3 H]^{3-})$  and 1279.7 (100,  $[M - 3 Et_3N - 2 H]^{2-}$ ) (C<sub>154</sub>H<sub>160</sub>N<sub>3</sub>O<sub>45</sub>P<sub>3</sub> requires M, 2863.95).

#### 2,3,4-Tri-*O*-benzoyl-β-D-galactopyranosyl-(1→4)-1-*O*-acetyl-2,3,6-tri-*O*-benzoyl-α-D-mannopyranose 12

A solution of compound  $11^{1}$  (200 mg) in pyridine (4 cm<sup>3</sup>) containing acetic anhydride (2 cm<sup>3</sup>) was kept overnight at room temperature and then concentrated to dryness. Toluene was twice evaporated off from the residue, which was then treated with 1% TFA in CH<sub>2</sub>Cl<sub>2</sub> (1-2 min; 0 °C) as described for the synthesis of compound 5. Column chromatography [tolueneethyl acetate, (85:15)] gave the disaccharide derivative 12 (116 mg, 73%) as an amorphous solid;  $[\alpha]_D^{24} + 101$  (c 1, CHCl<sub>3</sub>);  $R_{\rm f}$  0.26 (solvent E);  $\delta_{\rm H}$  2.19 (3 H, s, Ac), 3.01 (1 H, dd,  $J_{6a',6b'}$ 11.5, 6'-H<sup>a</sup>), 3.16 (1 H, dd, 6'-H<sup>b</sup>), 3.58 (1 H, t,  $J_{5',6a'} =$  $J_{5',6b'} = 6.4, 5'-H$ , 4.18 (1 H, ddd,  $J_{5,6a}$  3.0, 5-H), 4.49 (1 H, dd,  $J_{6a,6b}$  12.0, 6-H<sup>a</sup>), 4.60 (1 H, t,  $J_{3,4} = J_{4,5} = 9.4$ , 4-H), 4.69 (1 H, dd,  $J_{5,6b}$  2.0, 6-H<sup>b</sup>), 4.96 (1 H, d,  $J_{1',2'}$  7.9, 1'-H), 5.41 (1 H, dd,  $J_{2',3'}$  10.5, 3'-H), 5.59 (1 H, d,  $J_{3',4'}$  3.5, 4'-H), 5.65 (1 H, dd, J<sub>2.3</sub> 3.4, 2-H), 5.80 (1 H, dd, 2'-H), 5.89 (1 H, dd, 3-H), 6.26 (1 H, d, J<sub>1,2</sub> 2.0, 1-H) and 7.13-8.05 (30 H, m,  $6 \times Ph$ );  $\delta_{C} 21.05 (MeCO_{2})$ , 59.87 (C-6'), 61.93 (C-6), 68.45 (C-4'), 69.43 (C-2), 69.90 (C-3), 70.15 (C-2'), 71.39 (C-5), 71.75 (C-3'), 73.31 (C-4), 74.19 (C-5'), 90.67 (C-1), 101.30 (C-1'), 128.20-133.93 (Ph), 165.21–166.68 (PhCO<sub>2</sub>) and 168.47 (MeCO<sub>2</sub>); ES-MS(+): m/z 1031.3 (100%, [M + Na]<sup>+</sup>); ES-MS(-): m/z903.2 (38%,  $[M - PhCO]^{-}$ ), 965.1 (40,  $[M - MeCO]^{-}$ ), 1007.3 (100,  $[M - H]^{-}$ ), 1051.4 (25,  $[M + 2 Na - 3 H]^{-}$ ) and 1083.1 (45,  $[M + 2 K - 3 H]^{-}$ ) (C<sub>56</sub>H<sub>48</sub>O<sub>18</sub> requires M, 1008.29).

1564 J. Chem. Soc., Perkin Trans. 1, 1996

# 2,3,4-Tri-O-benzoyl- $\beta$ -D-galactopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-O-benzoyl- $\alpha$ -D-mannopyranose 6-[2,3,4,6-tetra-O-benzoyl- $\alpha$ -D-mannopyranosyl-(1 $\rightarrow$ 2)-3,4,6-tri-O-acetyl- $\alpha$ -D-mannopyranosyl phosphate], triethylammonium salt 14

A mixture of compounds 10<sup>1</sup> (167 mg, 0.159 mmol) and 12 (116 mg, 0.115 mmol) was dried by evaporation of pyridine  $(3 \times 1)$ cm<sup>3</sup>) therefrom. The residue was dissolved in pyridine (1 cm<sup>3</sup>), adamantane-1-carbonyl chloride (80 mg, 0.40 mmol) was added, and the mixture was stirred at 22 °C for 20 min, whereafter a freshly prepared solution of iodine (80 mg, 0.32 mmol) in pyridine-water (95:5; 2 cm<sup>3</sup>) was added and stirring was continued for 10 min. Conventional work-up, as described in the preparation of phosphodiester 4, then gave the crude product 13 ( $R_f$  0.40, solvent A), which was dissolved in MeCN-THF (1:1; 4 cm<sup>3</sup>), and the solution was cooled to -20 °C and treated with anhydrous dimethylamine (0.05 cm<sup>3</sup>, 0.75 mmol). The mixture was kept at 22 °C for 26 h, with monitoring by TLC (solvent B), whereafter a second portion of the reagent (0.05 cm<sup>3</sup>) was added. After a further 24 h, the mixture was concentrated and MeCN was evaporated off from the residue. Column chromatography  $[CH_2Cl_2-MeOH-Et_3N, (98.8)]$ 0.2:1) - $\rightarrow$  (95.1:3.9:1)] gave the tetrasaccharide monophosphate derivative 14 (180 mg, 77.7%) as an amorphous solid;  $[\alpha]_{D}^{24}$  + 13 (c 1, CHCl<sub>3</sub>); R<sub>f</sub> 0.56 (solvent B);  $\delta_{C}$  8.57 and 45.50 (Et), 20.71 (MeCO<sub>2</sub>), 62.03 (C-6, Man'), 62.33 (C-6, Man"), 62.49 (d, J<sub>C,P</sub> 5.4, C-6, Gal), 62.87 (C-6, Man), 65.90 (C-4, Man'), 66.58 (C-4, Man"), 67.67 (C-4, Gal), 68.48 (C-5, Man), 69.09 (C-5, Man'), 69.36 (C-3, Man"), 69.39 (C-3, Man), 69.74 (C-5, Man"), 70.24 (2 C, C-2, Gal + C-3, Man'), 70.63 (C-2, Man"), 71.54 (C-2, Man), 72.22 (d, J<sub>C,P</sub> 7.2, C-5, Gal), 72.36 (C-3, Gal), 73.31 (C-4, Man), 77.07 (d, J<sub>C,P</sub> 7.6, C-2, Man'), 91.92 (C-1, Man), 94.39 (br, C-1, Man'), 99.04 (C-1, Man"), 99.48 (C-1, Gal), 127.04-130.01 and 132.40-133.31 (Ph), 164.95-166.43  $(PhCO_2)$  and 169.29, 170.71 and 171.42  $(MeCO_2)$ ;  $\delta_P = -2.49$ (q,  $J_{P,H}$  8.8); FAB-MS(+): m/z 2016.04 (100%, [M + H]<sup>+</sup>)  $(C_{106}H_{104}NO_{37}P \text{ requires M, 2014.95}).$ 

#### 2,3,4-Tri-O-benzoyl-β-D-galactopyranosyl-(1→4)-2,3,6-tri-Obenzoyl-a-D-mannopyranosyl hydrogenphosphonate 6-[2,3,4,6tetra-O-benzoyl-α-D-mannopyranosyl-(1→2)-3,4,6-tri-O-acetyla-D-mannopyranosyl phosphate], bistriethylammonium salt 15 To a stirred solution of imidazole (91 mg, 1.33 mmol) in MeCN (2 cm<sup>3</sup>) at 0 °C was added phosphorus trichloride (0.035 cm<sup>3</sup>, 0.40 mmol), followed by triethylamine (0.20 cm<sup>3</sup>, 1.40 mmol). The mixture was stirred for 15 min, after which a solution of compound 14 (133 mg, 0.066 mmol) in MeCN (3 cm<sup>3</sup>) was added dropwise at 0 °C. The mixture was stirred overnight at room temperature and then quenched with 1 mol dm<sup>3</sup> TEA hydrogen carbonate (1 cm<sup>3</sup>). Work-up as described in the preparation of the compound 6 followed by column chromatography [CH<sub>2</sub>Cl<sub>2</sub>-MeOH-Et<sub>3</sub>N, (98.7:0.8:0.5)- $\rightarrow$ (93.5:6:0.5)], gave the tetrasaccharide H-phosphonate *derivative* 15 (93 mg, 64.6%) as an amorphous solid; $\lceil \alpha \rceil_{\rm P}^{24}$ +15 (c 1, CHCl<sub>3</sub>); $R_{\rm f}$ 0.40 (solvent B); $\delta_{\rm H}$ 1.26 (18 H, t, 6 × MeCH<sub>2</sub>), 2.02, 2.05 and 2.10 (9 H, 3 s, 3 × Ac), 3.02 (12 H, q, $6 \times MeCH_2$ ), 3.43–3.52 (2 H, m, 6-H<sub>2</sub>, Gal), 4.00–4.11 (2 H, m, 5-H and 6-H<sup>a</sup>, Man'), 4.16 (1 H, dd, J<sub>5,6</sub> 5.5 and 9.3, 5-H, Gal), 4.28-4.34 (3 H, m, 5-H, Man; 2-H and 6-H<sup>b</sup>, Man'), 4.54 $(1 \text{ H}, t, J_{3,4} = J_{4,5} = 9.6, 4\text{-H}, \text{Man}), 4.57 (1 \text{ H}, \text{dd}, J_{5,6a} 3.5,$ J<sub>6a,6b</sub> 12.0, 6-H<sup>a</sup>, Man), 4.64 (1 H, dd, J<sub>5,6b</sub> 1.5, 6-H<sup>b</sup>, Man), 4.66–4.72 (3 H, m, 5-H and 6-H<sub>2</sub>, Man"), 5.12 (1 H, d, J<sub>1,2</sub> 8.0, 1-H, Gal), 5.35 (1 H, d, J<sub>1,2</sub> 1.7, Man"), 5.40 (2 H, m, 3- and 4-H, Man'), 5.45 (1 H, dd, J<sub>2,3</sub> 10.6, 3-H, Gal), 5.67 (1 H, dd, J<sub>1,2</sub> 1.5, J<sub>1,P</sub> 8.5, 1-H, Man'), 5.68 (1 H, br, 2-H, Man), 5.69 (1 H, dd, 2-H, Gal), 5.72 (1 H, br d, J<sub>1,P</sub> 8.7, 1-H, Man), 5.77 (1 H, dd, J<sub>2,3</sub> 3.0, 2-H, Man"), 5.83 (1 H, dd, J<sub>2,3</sub> 3.5, 3-H, Man), 5.87 (1 H, d, J<sub>3,4</sub> 3.2, 4-H, Gal), 5.99 (1 H, dd, 3-H, Man"), 6.23 (1 H, t, $J_{3,4} = J_{4,5} = 10.0, 4$ -H, Man"), 7.01 (1 H, d, $J_{H,P}$ 640.0, HP) and 6.95–8.10 (50 H, m, 10 $\times$ Ph); $\delta_{\rm C}$ 8.61 and 45.72 (Et), 20.62 (MeCO<sub>2</sub>), 61.60 (d, J<sub>C.P</sub> 5.4, C-6, Gal), 62.03 (C-6, Man'),

62.40 (2 C, C-6, Man + C-6, Man"), 66.00 (C-4, Man'), 66.59 (C-4, Man"), 67.29 (C-4, Gal), 69.23 (C-5, Man'), 69.36 (C-3, Man"), 69.78 (C-5, Man"), 69.92 (C-5, Man), 70.18 (C-3, Man), 70.24 (C-2, Gal), 70.60 (C-3, Man'), 70.67 (C-2, Man"), 70.81 (d,  $J_{C,P} 6.3, C-2, Man), 71.74 (d, J_{C,P} 7.0, C-5, Gal), 72.27 (C-3, Gal), 73.41 (C-4, Man), 77.13 (d, C-2, Man'), 92.68 (br, <math>{}^{1}J_{C,H} 176.1$ , C-1, Man), 94.34 (d,  $J_{C,P} \sim 5.0, {}^{1}J_{C,H} 170.2, C-1, Man'), 99.01 ({}^{1}J_{C,H} 175.8, C-1, Man''), 101.18 ({}^{1}J_{C,H} 161.5, C-1, Gal), 127.80-130.05 and 132.42-133.29 (Ph), 164.78-166.15 (PhCO<sub>2</sub>), 169.10, 170.41 and 170.95 (MeCO<sub>2</sub>); <math>\delta_P 1.68 (dd, {}^{1}J_{P,H} 640.0, {}^{3}J_{P,H} 8.7, P) and -2.54 (dt, {}^{3}J_{P,H} 8.5 and 10.5, P'); FAB-MS(+): m/z 2017.45 (50\%, [M - 2 Et_3N + K]^+) and 2080.47 (95, [M - Et_3N + H]^+) (C_{112}H_{120}N_2O_{39}P_2 requires M, 2180.12). Also isolated was the starting material 14 (15 mg, 11.3\% recovery).$ 

## Dec-9-enyl 2,3,4-tri-O-benzoyl- $\beta$ -D-galactopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-O-benzoyl- $\alpha$ -D-mannopyranosyl phosphate, triethylammonium salt 17

The preparation of H-phosphonate 16 from compound 11 has been described recently.1 Compound 17 was prepared by condensation of the glycobiosyl H-phosphonate 16 (57 mg, 0.04 mmol) and dec-9-en-1-ol (0.021 cm<sup>3</sup>, 0.12 mmol) in the presence of adamantane-1-carbonyl chloride (20 mg, 0.10 mmol), followed by oxidation with iodine (20 mg, 0.08 mmol) (as described for the synthesis of compound 14) and subsequent dedimethoxytritylation with 1% TFA in CH<sub>2</sub>Cl<sub>2</sub> (1 min; 0 °C; as described in the preparation of compound 5). Column chromatography [CH<sub>2</sub>Cl<sub>2</sub>-MeOH-Et<sub>3</sub>N,  $(99:0:1) \longrightarrow (97:2:1)$ ] gave the biosyl phosphate derivative 17 (46 mg, 90%) as an amorphous solid;  $[\alpha]_{D}^{22}$  +64 (c 1, CHCl<sub>3</sub>);  $R_{f}$  0.23 (solvent A);  $\delta_{\rm C}$  8.64 and 45.66 (Et), 25.78, 28.99, 29.14, 29.39, 29.75 and 33.85 (CH<sub>2</sub>), 30.79 (d, J<sub>C,P</sub> 7.5, OCH<sub>2</sub>CH<sub>2</sub>), 60.23 (C-6'), 62.61 (C-6), 66.20 (d, J<sub>C.P</sub> 5.0, OCH<sub>2</sub>CH<sub>2</sub>), 68.60 (C-4'), 70.00 (2 C, C-3 and -5), 70.23 (C-2'), 70.81 (d, J<sub>C,P</sub> 7.4, C-2), 71.88 (C-3'), 73.09 (C-4), 74.31 (C-5'), 93.62 (d, J<sub>C,P</sub> 5.0, C-1), 100.63 (C-1'), 114.12 (CH=CH<sub>2</sub>), 128.35–131.13 and 133.11–133.77 (Ph), 139.39 (CH=CH<sub>2</sub>) and 165.17–165.90 (PhCO<sub>2</sub>);  $\delta_{\rm P}$  –1.40 (q,  $J_{P,H}$  7.0); FAB-MS(+): m/z 1287.0 (90%, [M + H]<sup>+</sup>) (C<sub>70</sub>H<sub>80</sub>NO<sub>20</sub>P requires M, 1286.37).

### Dec-9-enyl 2,3,4-tri-O-benzoyl- $\beta$ -D-galactopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-O-benzoyl- $\alpha$ -D-mannopyranosyl phosphate 6-{2,3,4tri-O-benzoyl- $\beta$ -D-galactopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-O-benzoyl- $\alpha$ -D-mannopyranosyl phosphate 6-[2,3,4,6-tetra-O-benzoyl- $\alpha$ -D-mannopyranosyl-(1 $\rightarrow$ 2)-3,4,6-tri-O-acetyl- $\alpha$ -D-mannopyranosyl phosphate]}, tristriethylammonium salt 18

This compound was prepared by condensation of the tetrasaccharide H-phosphonate block 15 (72 mg, 0.033 mmol) and the monohydroxylic disaccharide block 17 (30 mg, 0.023 mmol) in the presence of adamantane-1-carbonyl chloride (20 mg, 0.10 mmol) in pyridine  $(0.5 \text{ cm}^3)$  during 1 h, followed by oxidation with iodine (17 mg, 0.067 mmol), as described in the preparation of compound 14. Column chromatography  $[CH_2Cl_2-MeOH-Et_3N, (98.8:0.2:1) \longrightarrow (95:4:1)]$  gave the protected hexasaccharide triphosphate 18 (50 mg, 62%) as an amorphous solid;  $[\alpha]_{D}^{22} + 20.2$  (c 1, CHCl<sub>3</sub>);  $R_f 0.27$  (solvent A);  $\delta_C 8.40$  and 45.50 (Et), 20.66 (*Me*CO<sub>2</sub>), 25.90, 28.62–29.65 and 33.62 (CH<sub>2</sub>), 61.53 (2 C, br, C-6, Gal + C-6, Gal'), 61.96 (C-6, Man"), 62.21 (C-6, Man'), 62.40 (2 C, C-6, Man + C-6, Man"), 66.00 (C-4, Man"), 66.04 (d, J<sub>C,P</sub> 6.1, OCH<sub>2</sub>CH<sub>2</sub>), 66.60 (C-4, Man"), 67.25 (2 C, C-4, Gal + C-4, Gal'), 69.19 (C-5, Man"), 69.30 (C-3, Man'''), 69.78 (2 C, C-3, Man' + C-5, Man'''), 70.15, 70.23 and 70.28 (C-3, Man; C-5, Man; C-5, Man'), 70.38 (2 C, C-2, Gal + C-2, Gal'), 70.59 (d,  $J_{C,P} \sim 7.0$ , C-2, Man'), 70.66  $(2 \text{ C}, \text{C-2}, \text{Man}'' + \text{C-3}, \text{Man}''), 70.94 (d, J_{\text{C},P} \sim 7.0, \text{C-2}, \text{Man}),$ 71.71 (d,  $J_{C,P} \sim$  7.0, C-5, Gal'), 71.91 (d,  $J_{C,P} \sim$  7.0, C-5, Gal), 72.31 and 72.38 (C-3, Gal; C-3, Gal'), 73.28 and 73.48 (C-4, Man; C-4, Man'), 77.19 (d, J<sub>C.P</sub> ~7.0, C-2, Man"), 93.39 (br, C-1, Man') 93.52 (br, C-1, Man), 94.30 (br, C-1, Man"), 98.96

(C-1, Man<sup>*m*</sup>), 101.11 (C-1 Gal'), 101.20 (C-1, Gal), 113.94 (CH=CH<sub>2</sub>), 127.80–130.02 and 132.35–133.25 (Ph), 139.35 (CH=CH<sub>2</sub>), 164.75–166.12 (PhCO<sub>2</sub>) and 169.02, 170.30 and 170.87 (MeCO<sub>2</sub>);  $\delta_{\rm P}$  – 1.40 (q,  $J_{\rm P,H}$  6.5, P), – 2.56 (dt,  $J_{\rm P,H}$  8.0 and 10.0, P") and –3.05 (dt,  $J_{\rm P,H}$  7.1 and  $J_{\rm P,H}$  9.0, P'); ES-MS(–): m/z 1052.4 (100%, [M – Et<sub>3</sub>N – 3 H]<sup>3–</sup>) and 1579.1 (20, [M – 3 Et<sub>3</sub>N – 2 H]<sup>2–</sup>) (C<sub>182</sub>H<sub>198</sub>N<sub>3</sub>O<sub>59</sub>P<sub>3</sub> requires M, 3462.18).

# Dec-9-enyl $\beta$ -D-galactopyranosyl-(1 $\rightarrow$ 4)- $\alpha$ -D-mannopyranosyl phosphate $6^{Gal}$ -{ $\beta$ -D-galactopyranosyl-(1 $\rightarrow$ 4)- $\alpha$ -D-mannopyranosyl phosphate $6^{Gal}$ -[ $\alpha$ -D-mannopyranosyl-(1 $\rightarrow$ 2)- $\alpha$ -D-mannopyranosyl phosphate]}, tristriethylammonium salt 8

To a solution of compound 18 (50 mg) in MeOH-THF (4:1; 10 cm<sup>3</sup>) was added NaOMe in MeOH (4.6 mol dm<sup>-3</sup>; 0.11 cm<sup>3</sup>). The mixture was kept at 24 °C for 1.5 h and at 1 °C for 16 h, whereafter it was deionized with Dowex 50W-X4 (H<sup>+</sup>) resin, filtered and immediately neutralized with Et<sub>3</sub>N. After concentration, water (5  $\times$  10 cm<sup>3</sup>) was evaporated off from the residue to remove methyl benzoate. The hexasaccharide triphosphate 8 (23 mg, 95.3%) was thereby obtained as an amorphous solid;  $[\alpha]_D^{22} + 35$  (c 1, MeOH);  $\dot{R}_f 0.30$  (solvent D);  $\delta_{\rm H}({\rm D_2O})$  (*inter alia*) 1.29 (10 H, m, 5 × CH<sub>2</sub>) 1.62 (2 H, quintet, J6.5, OCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>), 2.05 (2 H, quartet, J6.5, CH<sub>2</sub>CH<sub>2</sub>CH=), 4.46 (1 H, d, J<sub>1,2</sub> 7.4, 1-H, Gal'), 4.47 (1 H, d, J<sub>1,2</sub> 7.4, 1-H, Gal), 4.96 (1 H, br d, J 10.1, CH=CH<sub>2</sub>), 5.04 (1 H, br d, J 17.0, CH=CH<sub>2</sub>), 5.06 (1 H, d, J<sub>1,2</sub> 1.2, 1-H, Man<sup>'''</sup>), 5.40 (1 H, dd, J<sub>1,2</sub> 1.2,  $J_{1,P}$  7.2, 1-H, Man), 5.43 (1 H, dd,  $J_{1,2}$  1.2,  $J_{1,P}$  7.2, 1-H, Man'), 5.65 (1 H, dd, J<sub>1,2</sub> 1.2, J<sub>1,P</sub> 7.2, 1-H, Man") and 5.92 [1 H, ddt,  $J(H, CH_2)$  6.5,  $CH_2CH=CH_2$ ];  $\delta_P(D_2O) - 0.91$  (P) and -1.24 (P' + P'') (ratio 1:2);  $\delta_c$ , see Table 1; ES-MS(-): m/z455.3 (100%,  $[M - 3 Et_3N - 3 H]^{3-}$ ), 683.3 (50,  $[M - 3 H]^{3-}$ )  $Et_3N - 2H]^{2^-}$ , 694.4 (65,  $[M - 3Et_3N - 3H + Na]^{2^-}$ ),  $1367.4(1, [M - 3 Et_3N - H]^-), 1389.5(2, [M - 3 Et_3N - 2))$  $H + Na]^{-}$ ) and 1411.5 (3,  $[M - 3 Et_3N - 3 H + 2 Na]^{-}$ ) (C<sub>64</sub>H<sub>128</sub>N<sub>3</sub>O<sub>40</sub>P<sub>3</sub> requires M, 1671.73).

### Dec-9-enyl $\beta$ -D-galactopyranosyl-(1 $\rightarrow$ 4)- $\alpha$ -D-mannopyranosyl phosphate, triethylammonium salt 9

O-Debenzoylation of compound 17 (14 mg) with NaOMe in MeOH (0.05 mol dm<sup>-3</sup>) (1 h; 24 °C), followed by work-up as in the preceding experiment gave the dec-9-enyl glycobiosyl phosphate 9 (7 mg, 97.2%) as an amorphous solid;  $[\alpha]_{\rm D}^{22} + 21.5$ (c 0.7, MeOH);  $R_f$  0.65 (solvent D);  $\delta_H$ (D<sub>2</sub>O) 1.31 (19 H, m,  $3 \times MeCH_2$  and  $5 \times CH_2$ ), 1.63 (2 H, quintet, J 6.5, OCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>), 2.05 (2 H, quartet, J 6.5, CH<sub>2</sub>CH<sub>2</sub>CH=), 3.21 (6 H, quartet,  $3 \times \text{MeCH}_2$ ), 3.56 (1 H, dd,  $J_{2',3'}$  10.0, 2'-H), 3.68 (1 H, dd, J<sub>3',4'</sub> 3.0, 3'-H), 3.76 (2 H, m, 5'- and 6'-H<sup>a</sup>), 3.82  $(1 \text{ H}, \text{ dd}, J_{5',6b'} 9.0, J_{6a',6b'} 12.0, 6'-\text{H}^{b}), 3.86-3.96 (7 \text{ H}, \text{m}, 4-,$ 4'- and 5-H, 6-H<sub>2</sub> and  $OCH_2CH_2$ ), 4.02 (1 H, dd,  $J_{3,4}$  9.0, 3-H), 4.04 (1 H, dd,  $J_{2,3}$  3.0, 2-H), 4.46 (1 H, d,  $J_{1',2'}$  7.5, 1'-H), 4.98 (1 H, dd,  ${}^{2}J_{H,H}$  2.0,  ${}^{3}J_{H,H}$  10.0, CH=CH<sub>2</sub>), 5.06 (1 H, dd,  ${}^{3}J_{H,H}$  17.5, CH= $CH_2$ ), 5.41 (1 H, dd,  $J_{1,2}$  1.5,  $J_{1,P}$  7.5, 1-H) and 5.93 [1 H, ddt,  $J(\tilde{H}, CH_2)$  6.5,  $CH_2CH=CH_2$ ];  $\delta_P(D_2O) - 1.04$ ;  $\delta_C$ , see Table 1; ES-MS(-): m/z 559.3 (100%,  $[M - Et_3N - H]^-$ ), 663.4 (3,  $[M - Et_3N - 5 H + 3 Na + K]^-$ ), 1119.5 (5, [2  $M - 2 Et_3 N - H$ ]<sup>-</sup>) and 1141.5 (4, [2 M - 2  $Et_3 N - 2 H +$ Na]<sup>-</sup>) ( $C_{28}H_{56}NO_{14}P$  requires M, 661.34).

#### Acknowledgements

The research of A. V. N. was supported by a Wellcome Trust International Grant and by an International Research Scholar's award from the Howard Hughes Medical Institute. We are grateful to Dr. B. N. Green of VG BIOTECH, Cheshire, for ES-MS analyses.

#### References

1 Part 4, A. V. Nikolaev, T. J. Rutherford, M. A. J. Ferguson and J. S. Brimacombe, J. Chem. Soc., Perkin Trans. 1, 1995, 1977.

- 2 M. J. McConville and M. A. J. Ferguson, *Biochem. J.*, 1993, **294**, 305.
- 3 E. Barreto-Bergter and P. A. J. Gorin, Adv. Carbohydr. Chem. Biochem., 1983, 41, 67.
- 4 L. Kenne and B. Lindberg, in *The Polysaccharides*, ed. G. O. Aspinall, Academic Press, New York, 1983, vol. 2, pp. 287–363.
- 5 P. Westerduin, G. H. Veeneman, G. A. van der Marel and J. H. van Boom, *Tetrahedron Lett.*, 1986, **27**, 6271.
- 6 A. V. Nikolaev, I. A. Ivanova, V. N. Shibaev and N. K. Kochetkov, *Carbohydr. Res.*, 1990, **204**, 65.
- 7 G. I. Eliseeva, I. A. Ivanova, A. V. Nikolaev and V. N. Shibaev, Sov. J. Bioorg. Chem., 1991, 17, 808 (Engl. Transl.).
- 8 A. V. Nikolaev, J. A. Chudek and M. A. J. Ferguson, *Carbohydr. Res.*, 1995, **272**, 179.
- 9 A. V. Nikolaev, I. A. Ivanova and V. N. Shibaev, *Carbohydr. Res.*, 1993, **242**, 91.

- 10 J. V. O'Connor, H. A. Nunez and R. Barker, *Biochemistry*, 1979, 18, 500.
- 11 A. V. Nikolaev, I. A. Ivanova, V. N. Shibaev and A. V. Ignatenko, Sov. J. Bioorg. Chem., 1991, 17, 908 (Engl. Transl.).
- 12 P. J. Garegg, T. Regberg, J. Stawinski and R. Stromberg, Nucleosides, Nucleotides, 1987, 6, 655.
- 13 V. A. Efimov, I. Y. Dubey and O. G. Chakhmakhcheva, Nucleosides, Nucleotides, 1990, 9, 473.
- 14 L. Proudfoot, A. V. Nikolaev, M. A. J. Ferguson, J. S. Brimacombe and F. Y. Liew, *Proc. Natl. Acad. Sci. USA*, submitted for publication.

Paper 5/08103C Received 12th December 1995 Accepted 22nd February 1996